Resource Summary Report

Generated by RRID on Jul 29, 2026

PE anti-human CD34

RRID:AB_1731937
Type: Antibody

Proper Citation

BioLegend Cat# 343505, RRID:AB_1731937

Antibody Information

URL: http://antibodyregistry.org/AB_1731937

Proper Citation: BioLegend Cat# 343505, RRID:AB_1731937

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD34

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: Clone 581

Antibody ID: AB_1731937

Vendor: BioLegend

Catalog Number: 343505

Alternative Catalog Numbers: 343506

Record Creation Time: 20250820T065424+0000

Record Last Update: 20250821T011058+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD34.

No alerts have been found for PE anti-human CD34.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR protocols, 6(2), 103742.

Fang Y, et al. (2025) Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. STAR protocols, 6(2), 103810.

Bakbak E, et al. (2024) Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial. Med (New York, N.Y.), 5(7), 718.

Conover CA, et al. (2024) PAPP-A as a Potential Target in Thyroid Eye Disease. The Journal of clinical endocrinology and metabolism, 109(12), 3119.

Albert V, et al. (2024) HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. International journal of molecular sciences, 25(13).

Rivera M, et al. (2024) Protocol for in vitro co-culture assay for rapid expansion of human T cell acute lymphoblastic leukemia. STAR protocols, 5(2), 103103.

Bruss C, et al. (2024) Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative - specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy. Frontiers in immunology, 15, 1355130.